June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Risk factors for glaucoma progression in the United Kingdom Glaucoma Treatment Study (UKGTS)
Author Affiliations & Notes
  • Panayiota Founti
    National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
  • Ana Quartilho
    National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
  • Catey V Bunce
    National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
    Department of Primary Care & Public Health Sciences, King's College London, London School of Hygiene & Tropical Medicine, London, United Kingdom
  • Caroline J Dore
    National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
    Comprehensive Clinical Trials Unit, University College London, London, United Kingdom
  • Jibran Mohamed-Noriega
    National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
    Departamento de Oftalmología, Hospital Universitario, UANL, México, Monterrey, Mexico
  • David Garway-Heath
    National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
  • Footnotes
    Commercial Relationships   Panayiota Founti, None; Ana Quartilho, None; Catey Bunce, None; Caroline Dore, None; Jibran Mohamed-Noriega, None; David Garway-Heath, Aerie (R), Alcon (F), Alcon (R), Alimera (R), Allergan (R), NIHR i4i programme (F), Pfizer (F), Pfizer (R), Quark (R), Quethera (R), Santen (R), Santhera (R), Sensimed (R)
  • Footnotes
    Support  Unrestricted investigator-initiated research grant from Pfizer, and supplementary funding from the UK’s NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK.
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 2464. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Panayiota Founti, Ana Quartilho, Catey V Bunce, Caroline J Dore, Jibran Mohamed-Noriega, David Garway-Heath; Risk factors for glaucoma progression in the United Kingdom Glaucoma Treatment Study (UKGTS). Invest. Ophthalmol. Vis. Sci. 2017;58(8):2464.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To identify factors associated with visual field (VF) deterioration in the United Kingdom Glaucoma Treatment Study (UKGTS).

Methods : The UKGTS is the first randomised, double-masked, placebo-controlled, multicentre trial on the visual field (VF) preserving effect of medical treatment in open-angle glaucoma (OAG). Five hundred sixteen participants with previously untreated OAG were randomized to either latanoprost 0.005% or placebo. Eligibility criteria were modeled on those for the Early Manifest Glaucoma Trial. The observation period was 2 years, with subjects monitored by VF testing, among other procedures, at 11 visits. VF deterioration was based on the Guided Progression Analysis pattern deviation maps. Frailty models (extension of the Cox proportional model) were fitted to compute the hazard ratios (HRs) and respective 95% confidence intervals (CIs) for time to progression whilst accounting for the correlation within sites. Model selection was guided by backwards stepwise selection conducted on the model containing all variables which were significant at the 0.2 level in the univariable analysis.

Results : Treatment with latanoprost reduced the HR for VF deterioration by 54% (HR, 0.46; 95% CI, 0.30-0.73, p=0.001). Progression factors were higher baseline mean intraocular pressure (HR, 1.05 per mmHg; 95% CI, 1.004-1.106, p=0.03) and disk haemorrhage at any visit (HR, 1.68; 95% CI, 1.09-2.60, p=0.02). Smoking (current or previous) was associated with reduced HR for VF deterioration (HR, 0.63; 95% CI, 0.41-0.98, p=0.04). No other factors were found to be statistically significant in the multivariable analysis.

Conclusions : In the UKGTS, treatment with latanoprost halved progression risk. Previously reported progression factors for OAG were incorporated in the model, and only disc haemorrhage and baseline intraocular pressure were confirmed. The association of smoking history requires further exploration to assess for potential confounding.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×